Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Case Report: A case of infantile acute hyperleukocytic leukemia treated by leukapheresis.
Front Pediatr
December 2024
Department of Hematology and Oncology, Dalian Women and Children's Medical Group, Dalian, China.
Leukapheresis is a treatment used to reduce leukocytes to decrease the number of white blood cells in circulation and prevent the risks of hyperviscosity and cerebrovascular and pulmonary leukostasis. We present a case of pro-B-cell acute lymphoblastic leukemia (ALL) with hyperleukocytosis in a 6-month-old infant, characterized by a positive KMT2A/AFF1 fusion gene with a leukocyte count of 1,755 × 10/L. After two consecutive sessions of leukapheresis, the white blood cell count decreased to 55 × 10/L.
View Article and Find Full Text PDFLeukoreduction in a dog with acute leukemia.
J Vet Intern Med
December 2024
Friendship Hospital for Animals, Washington, District of Columbia, USA.
A 9-year-old male castrated golden retriever cross was evaluated for an acute onset of ataxia. A complete blood count revealed marked leukocytosis, anemia, and thrombocytopenia. Leukocytosis was characterized by marked lymphocytosis, monocytosis, neutropenia, and eosinopenia.
View Article and Find Full Text PDFEfficient manufacturing of CAR-T cells from whole blood: a scalable approach to reduce costs and enhance accessibility in cancer therapy.
Cytotherapy
December 2024
Department of Transfusion Medicine, Center for Cellular Engineering, National Institutes of Health, Bethesda, Maryland, USA. Electronic address:
Background: Chimeric antigen receptor T (CAR-T) cells have significantly advanced the treatment of cancers such as leukemia and lymphoma. Traditionally, T cells are collected from patients through leukapheresis, an expensive and potentially invasive process that requires specialized equipment and trained personnel. Although whole blood collections are much more technically straightforward, whole blood starting material has not been widely utilized for clinical CAR-T cell manufacturing, in part due to lack of manufacturing processes designed for use in a good manufacturing practice (GMP) environment.
View Article and Find Full Text PDFReal-world Outcomes of Commercial Tisagenlecleucel for Children, Adolescents, and Young Adults With Acute Lymphoblastic Leukemia in Japan.
Transplant Cell Ther
November 2024
Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Chimeric antigen receptor (CAR) T cells are a major new treatment option for children, adolescents, and young adults (CAYA) patients with relapsed and refractory (R/R) B cell acute lymphoblastic leukemia (B-ALL). Therefore, accumulating evidence from real-world experiences of CAR-T outcomes in various regions worldwide is important, particularly when comparing outcomes of patients with differing medical and ethnic backgrounds. More than 5 years have passed since tisagenlecleucel was approved in Japan.
View Article and Find Full Text PDF[Image of cerebral leukostasis in a context of acute leukemia].
Rev Med Liege
November 2024
Service de Pédiatrie, département d'Hémato-oncologie pédiatrique, CHU Liège, Belgique.
Leukostasis is a classic and well-known complication of acute leukemia when major hyperleukocytosis is present. It affects some organs, notably the central nervous system. The symptoms of cerebral leukostasis are diverse and vary in intensity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!